A trial HIV vaccine triggered elusive and essential antibodies in humans
An HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial. The finding, reported May 17 in the journal Cell, not only provides proof that a vaccine can elicit these antibodies … Read more
